FIG 2 .
PICLC protects CGD mice against A. nidulans infection. CGD mice were treated with either PICLC (15 μg PICLC in 30 μl PBS/mouse) or PBS via pharyngeal aspiration 24 h pre- and post-infection with A. nidulans (5 × 103 conidia/mouse). (A) The survival of mice (n = 6) was monitored for 28 days. (B) Lungs from infected mice were taken at 3 and 15 days postinfection (n = 8), and fungal burdens were estimated by measuring fungal DNA by qPCR. *, P ≤ 0.05. (C) Montaged 25× images of H&E-stained sections taken 3 days postinfection showing size and frequency of infectious foci in PICLC immunotherapy and control mice. Bar, 2 mm. (D) Higher-magnification images of infectious foci at 3 days postinfection (pi) (top row) and granuloma at 15 days postinfection (bottom row). Left columns, H&E-stained sections; right columns, GMS-stained sections. Bars, 100 µm (H&E images) and 50 µm (GMS images).